Davis Polk advised Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC as joint book-running managers and representatives of the several underwriters in connection with the $192.28 million initial public offering of 8,740,000 shares of common stock of Ophthotech Corporation, which included 1,140,000 shares from the exercise of the underwriters’ over-allotment option in full. The common stock is listed on the NASDAQ Global Select Market under the symbol “OPHT.”  

Based in New York and New Jersey, Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. Ophthotech’s most advanced product candidate is Fovista, which is being developed for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet age-related macular degeneration, or wet AMD.  

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Christopher R. Bornhorst and Rashna Bhojwani. The intellectual property team included associate Bruce Rose-Innes and law clerk Natalie A. Thomas. Partner Harry Ballan and associate Rachel Lerner provided tax advice. The environmental team included counsel Loyti Cheng and associate Kevin J. Klesh. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.